A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor

2021-07-01
Rajpoot, Sajjan
Ohishi, Tomokazu
Kumar, Ashutosh
Pan, Qiuwei
Banerjee, Sreeparna
Zhang, Kam Y. J.
Baig, Mirza S.
Show full item record
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
149
views
82
downloads
Background and Objective Coronavirus disease 2019 is a novel disease caused by the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 virus. It was first detected in December 2019 and has since been declared a pandemic causing millions of deaths worldwide. Therefore, there is an urgent need to develop effective therapeutics against coronavirus disease 2019. A critical step in the crosstalk between the virus and the host cell is the binding of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein to the peptidase domain of the angiotensin-converting enzyme 2 (ACE2) receptor present on the surface of host cells. Methods An in silico approach was employed to design a 13-amino acid peptide inhibitor (13AApi) against the RBD of the SARS-CoV-2 spike protein. Its binding specificity for RBD was confirmed by molecular docking using pyDockWEB, ClusPro 2.0, and HDOCK web servers. The stability of 13AApi and the SARS-CoV-2 spike protein complex was determined by molecular dynamics simulation using the GROMACS program while the physicochemical and ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of 13AApi were determined using the ExPASy tool and pkCSM server. Finally, in vitro validation of the inhibitory activity of 13AApi against the spike protein was performed by an enzyme-linked immunosorbent assay. Results In silico analyses indicated that the 13AApi could bind to the RBD of the SARS-CoV-2 spike protein at the ACE2 binding site with high affinity. In vitro experiments validated the in silico findings, showing that 13AApi could significantly block the RBD of the SARS-CoV-2 spike protein. Conclusions Blockage of binding of the SARS-CoV-2 spike protein with ACE2 in the presence of the 13AApi may prevent virus entry into host cells. Therefore, the 13AApi can be utilized as a promising therapeutic agent to combat coronavirus disease 2019.
https://hdl.handle.net/11511/91570
Department of Biology, Article

Suggestions

Assessment of the immunogenicity and formulation of recombinant proteins from SARS-CoV-2 as vaccine antigens
Keser, Duygu; Özcengiz, Gülay; Department of Biology (2022-9-15)
COVID-19 is an infectious disease caused by SARS-CoV-2. The virus was first detected in Wuhan, China in late 2019, and the outbreak was declared a pandemic in January 2020 by WHO, and continues to spread worldwide. As of July 2022, more than 575 million confirmed cases have been detected all over the world, and more than 6 million people died from the disease. One of the most important public health measures in combating the spread of infectious diseases is vaccination. Despite the existence of rapidly deve...
Selecting 2-FY RNA Aptamers Against SARS-CoV-2 Particle
Öztürk, Meriç; Gözen, Ayşe Gül; İlgü, Müslüm; Department of Molecular Biology and Genetics (2021-6-22)
Corona Virus Disease – 19 (COVID-19) is caused by infection of SARS-CoV-2 from other humans and animals, which results in clinical symptoms like fever, cough, breathing difficulties headache, muscle pain, and diarrhea. Further symptoms can be life threatening clinical conditions such as pneumonia, cardiovascular and rarely neurological complexities. According to studies, estimated fatality rate of the disease is about 4 %; reported cases-fatality rate is about 2.3 %. Early diagnosis is crucial to prevent fu...
A comprehensive analysis of Bordetella pertussis surface proteome and identification of new immunogenic proteins
Tefon, Burcu E.; Maass, Sandra; Ozcengiz, Erkan; Becher, Doerte; Hecker, Michael; Özcengiz, Gülay (2011-04-27)
Whooping cough, caused by the gram negative pathogen Bordetella pertussis, is a worldwide acute respiratory disease that predominantly involves infants. In the present study, surface proteins of B. pertussis Tohama I and Saadet strains were identified by using 2DE followed by MALDI-TOF-MS/MS analysis and also geLC-MS/MS. With these approaches it was possible to identify 45 and 226 proteins, respectively. When surface proteins of the strains were separated by 2DE and analyzed by Western blotting for their re...
Generation and characterization of human induced pluripotent stem cell line METUi001-A from a 25-year-old male patient with relapsing-remitting multiple sclerosis
Koc, Dilara; Begentaş, Onur Can; Yurtogullari, Sukran; Temel, Musa; Akcali, Kamil Can; Demirkaya, Seref; Kiriş, Erkan (2021-05-01)
Multiple sclerosis is a chronic disease characterized by inflammation, demyelination, and axonal damage in the central nervous system. Here, we established an induced pluripotent stem cell (iPSC) line METUi001-A from the peripheral blood mononuclear cells of a 25-year-old male individual with clinically diagnosed Relapsing-Remitting Multiple Sclerosis (RRMS) using the integration-free Sendai reprogramming method. We demonstrated that the iPSCs are free of exogenous Sendai reprogramming vectors, have a norma...
A comparative study on EpCAM antibody immobilization on gold surfaces and microfluidic channels for the detection of circulating tumor cells
Cetin, Didem; Okan, Meltem; Bat, Erhan; Külah, Haluk (2020-04-01)
Detection of circulating tumor cells (CTCs) from the bloodstream holds great importance to diagnose cancer at early stages. However, CTCs being extremely rare in blood makes them difficult to reach. In this paper, we introduced different surface modification techniques for the enrichment and detection of MCF-7 in microfluidic biosensor applications using gold surface and EpCAM antibody. Mainly, two different mechanisms were employed to immobilize the antibodies; covalent bonding and bioaffinity interaction....
Citation Formats
S. Rajpoot et al., “A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor,” DRUGS IN R&D, pp. 273–283, 2021, Accessed: 00, 2021. [Online]. Available: https://hdl.handle.net/11511/91570.
METU IIS - Integrated Information Service open@metu.edu.tr